Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

Michael Dickinson; David Ritchie; Daniel J. Deangelo; Andrew Spencer; Oliver G. Ottmann; Thomas Fischer; Kapil N. Bhalla; Angela Liu; Katie Parker; Jeffrey W. Scott; Mark Bishton; H. Miles Prince

doi:10.1111/j.1365-2141.2009.07837.x

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

Michael Dickinson, David Ritchie, Daniel J. Deangelo, Andrew Spencer, Oliver G. Ottmann, Thomas Fischer, Kapil N. Bhalla, Angela Liu, Katie Parker, Jeffrey W. Scott, Mark Bishton, H. Miles Prince

Dr. Mary and Ron Neal Cancer Center

Research output: Contribution to journal › Article › peer-review

85 Scopus citations

Abstract

There are few treatment options for patients with Hodgkin Lymphoma (HL) who relapse after conventional therapies. Panobinostat is an orally available pan deacetylase inhibitor with evidence of activity in myeloid malignancies and cutaneous T cell lymphoma. Thirteen HL patients were treated with escalating doses of this novel agent in a phase IA/II multicentre study. A computed tomography partial response was achieved in 5/13(38%), and a metabolic response by ¹⁸F-fluoro-2-deoxy-d- glucose positron emission tomography scanning in 7/12 (58%) evaluable patients. This report describes the preliminary evidence of anti-tumour activity seen in the early phase of this study, which recently closed to accrual.

Original language	English (US)
Pages (from-to)	97-101
Number of pages	5
Journal	British Journal of Haematology
Volume	147
Issue number	1
DOIs	https://doi.org/10.1111/j.1365-2141.2009.07837.x
State	Published - Oct 2009

Keywords

HDAC inhibitor
Hodgkin lymphoma
LBH589
Panobinostat

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/j.1365-2141.2009.07837.x

Cite this

Dickinson, M., Ritchie, D., Deangelo, D. J., Spencer, A., Ottmann, O. G., Fischer, T., Bhalla, K. N., Liu, A., Parker, K., Scott, J. W., Bishton, M., & Miles Prince, H. (2009). Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. British Journal of Haematology, 147(1), 97-101. https://doi.org/10.1111/j.1365-2141.2009.07837.x

Dickinson, M, Ritchie, D, Deangelo, DJ, Spencer, A, Ottmann, OG, Fischer, T, Bhalla, KN, Liu, A, Parker, K, Scott, JW, Bishton, M & Miles Prince, H 2009, 'Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma', British Journal of Haematology, vol. 147, no. 1, pp. 97-101. https://doi.org/10.1111/j.1365-2141.2009.07837.x

@article{bf414d3a0f6e4d809cc492b58ebaa4ef,

title = "Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma",

abstract = "There are few treatment options for patients with Hodgkin Lymphoma (HL) who relapse after conventional therapies. Panobinostat is an orally available pan deacetylase inhibitor with evidence of activity in myeloid malignancies and cutaneous T cell lymphoma. Thirteen HL patients were treated with escalating doses of this novel agent in a phase IA/II multicentre study. A computed tomography partial response was achieved in 5/13(38%), and a metabolic response by 18F-fluoro-2-deoxy-d- glucose positron emission tomography scanning in 7/12 (58%) evaluable patients. This report describes the preliminary evidence of anti-tumour activity seen in the early phase of this study, which recently closed to accrual.",

keywords = "HDAC inhibitor, Hodgkin lymphoma, LBH589, Panobinostat",

author = "Michael Dickinson and David Ritchie and Deangelo, {Daniel J.} and Andrew Spencer and Ottmann, {Oliver G.} and Thomas Fischer and Bhalla, {Kapil N.} and Angela Liu and Katie Parker and Scott, {Jeffrey W.} and Mark Bishton and {Miles Prince}, H.",

year = "2009",

month = oct,

doi = "10.1111/j.1365-2141.2009.07837.x",

language = "English (US)",

volume = "147",

pages = "97--101",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley",

number = "1",

}

TY - JOUR

T1 - Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

AU - Dickinson, Michael

AU - Ritchie, David

AU - Deangelo, Daniel J.

AU - Spencer, Andrew

AU - Ottmann, Oliver G.

AU - Fischer, Thomas

AU - Bhalla, Kapil N.

AU - Liu, Angela

AU - Parker, Katie

AU - Scott, Jeffrey W.

AU - Bishton, Mark

AU - Miles Prince, H.

PY - 2009/10

Y1 - 2009/10

N2 - There are few treatment options for patients with Hodgkin Lymphoma (HL) who relapse after conventional therapies. Panobinostat is an orally available pan deacetylase inhibitor with evidence of activity in myeloid malignancies and cutaneous T cell lymphoma. Thirteen HL patients were treated with escalating doses of this novel agent in a phase IA/II multicentre study. A computed tomography partial response was achieved in 5/13(38%), and a metabolic response by 18F-fluoro-2-deoxy-d- glucose positron emission tomography scanning in 7/12 (58%) evaluable patients. This report describes the preliminary evidence of anti-tumour activity seen in the early phase of this study, which recently closed to accrual.

AB - There are few treatment options for patients with Hodgkin Lymphoma (HL) who relapse after conventional therapies. Panobinostat is an orally available pan deacetylase inhibitor with evidence of activity in myeloid malignancies and cutaneous T cell lymphoma. Thirteen HL patients were treated with escalating doses of this novel agent in a phase IA/II multicentre study. A computed tomography partial response was achieved in 5/13(38%), and a metabolic response by 18F-fluoro-2-deoxy-d- glucose positron emission tomography scanning in 7/12 (58%) evaluable patients. This report describes the preliminary evidence of anti-tumour activity seen in the early phase of this study, which recently closed to accrual.

KW - HDAC inhibitor

KW - Hodgkin lymphoma

KW - LBH589

KW - Panobinostat

UR - http://www.scopus.com/inward/record.url?scp=70349194470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349194470&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07837.x

DO - 10.1111/j.1365-2141.2009.07837.x

M3 - Article

C2 - 19663825

AN - SCOPUS:70349194470

SN - 0007-1048

VL - 147

SP - 97

EP - 101

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this